Video

Dr. Kuzel on Immunotherapy as a Targeted Approach to Cancer

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.

Timothy M. Kuzel, MD, FACP, chief, Hematology Oncology and Cell Therapy, Rush University Medical Center, discusses the use of immunotherapy as a targeted approach to treating cancer.

Over the past few years, many new approaches and agents have been developed to treat patients with a variety of cancers, including kidney cancer, melanoma, bladder cancer, and more, according to Kuzel. Compared with previous years, Kuzel believes this year has seen fewer novel drugs and big trials with paradigm shifts; rather, there are more data refining the way these drugs should be used. Kuzel has seen studies examining genetic sequencing and mutations in certain tumors, which has an impact on the response to immunotherapy.

The medical community is starting to think of immunotherapy as a targeted approach to cancer rather than a broad therapeutic approach, according to Kuzel.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD